Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Institut Gustave Roussy, University of Paris Sud, Villejuif, France



Survival: 19.2 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Villejuif
   
Hospital: Institut Gustave Roussy, University of Paris Sud
   
Journal: Link
   
Date: 4/2013

Description:
Patients:
This phase 3 study involved metastatic castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 524 male patients with a median age of 68 years. Group B had 528 male patients with a median age of 68 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent zibotentan, which is an inhibitor of the endothelin A receptor and interferes with cancer progression.

Patients in group B were treated with docetaxel and a placebo.

Toxicities:
There were two treatment-related deaths due to heart failure in group A. Grade 1-2 alopecia and grade 3-4 peripheral swelling was also reported.

There was one treatment-related death in group B that was due to heart failure. Grade 3-4 neutropenia and leukopenia were also reported.

Results:
The median overall survival for groups A and B was 20.0 and 19.2 months, respectively.

Support:
This study was supported by AstraZeneca.

Correspondence: Dr. Karim Fizazi; email: fizazi@igr.fr

E-mail to a Friend Email Physician More Information